Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| GN Invest | Healthcare Services | 16.0% | 68th pct | 268 |
| Gadaudebeli Meditsinis … | Healthcare Services | — | no FY data | 268 |
| Med-Laini | Healthcare Services | — | no FY data | 268 |
| Katastropis, Kritikuli … | Healthcare Services | — | no FY data | 268 |
| Janmrteli Tskhovreba | Healthcare Services | — | no FY data | 268 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
Only 1 of 5 peers filed FY2024. Switch to FY2021 (4 of 5).
| Ratio — FY 2024 | GN Invest | Gadaudebeli Meditsinis … | Med-Laini | Katastropis, Kritikuli … | Janmrteli Tskhovreba |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 94.1% | — | — | — | — |
| EBITDA Margin | 16.0% | — | — | — | — |
| EBITDAR | 78 | — | — | — | — |
| EBITDAR Margin | 27.9% | — | — | — | — |
| EBIT Margin | -4.4% | — | — | — | — |
| Net Profit Margin | -4.4% | — | — | — | — |
| Operating Expense % of Sales | 78.1% | — | — | — | — |
| Returns | |||||
| Return on Assets (ROA) | -1.2% | — | — | — | — |
| Return on Equity (ROE) | N/A | — | — | — | — |
| ROIC [EBIT / Invested Capital] | N/A | — | — | — | — |
| Leverage & debt balances | |||||
| Debt-to-Assets | 1.0% | — | — | — | — |
| Debt-to-Equity | -0.01x | — | — | — | — |
| Debt-to-EBITDA | 0.22x | — | — | — | — |
| Equity-to-Assets | -68.8% | — | — | — | — |
| Net Debt | -98 | — | — | — | — |
| Cash & Equivalents | 108 | — | — | — | — |
| Total Debt | 10 | — | — | — | — |
| Liquidity & working capital | |||||
| Current Ratio | 0.38x | — | — | — | — |
| Quick Ratio | 0.38x | — | — | — | — |
| Cash Ratio | 0.08x | — | — | — | — |
| Total Current Assets | 516 | — | — | — | — |
| Total Current Liabilities | 1,372 | — | — | — | — |
| Inventory | N/A | — | — | — | — |
| Trade Receivables | 74 | — | — | — | — |
| Trade Payables | 1,372 | — | — | — | — |
| Net Working Capital | -856 | — | — | — | — |
| Net Working Capital % of Revenue | -306.2% | — | — | — | — |
| Trade Working Capital | -1,297 | — | — | — | — |
| Trade Working Capital % of Revenue | -464.2% | — | — | — | — |
| Change in Trade Working Capital | N/A | — | — | — | — |
| Turnover & efficiency | |||||
| Inventory Turnover | N/A | — | — | — | — |
| Days Inventory Outstanding (DIO) | N/A | — | — | — | — |
| Receivables Turnover | 3.77x | — | — | — | — |
| Days Sales Outstanding (DSO) | 96.9 | — | — | — | — |
| Payables Turnover | 0.01x | — | — | — | — |
| Days Payable Outstanding (DPO) | 30454.8 | — | — | — | — |
| Cash Conversion Cycle | -30357.9 days | — | — | — | — |
| Asset Turnover | 0.28x | — | — | — | — |
| Cash flow & dividends | |||||
| Operating Cash Flow | -21 | — | — | — | — |
| Free Cash Flow (OCF − Capex proxy) | -21 | — | — | — | — |
| Cash Conversion (OCF / EBITDA) | -47.0% | — | — | — | — |
| Dividends Declared | N/A | — | — | — | — |
| Dividend Payout Ratio | N/A | — | — | — | — |